IOL Chemicals and Pharmaceuticals has announced that the European Directorate for the Quality of Medicines & Health Care (EDQM) has granted a Certificate of Suitability (CEP) for its active pharmaceutical ingredient Minoxidil. The approval was issued on 4 December 2025 under Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements.
The CEP confirms that the company’s Minoxidil API meets the standards laid out in the European Pharmacopoeia. Minoxidil is widely used as a topical treatment for hereditary hair loss, and the certification allows the product to be supplied to regulated European markets that require this level of compliance.
The company stated that the approval strengthens its position in the API segment and aligns with quality requirements in international markets. The grant of the certificate enables customers to rely on EDQM’s assessment rather than submitting their own detailed evaluations, simplifying the approval pathway for finished-dosage manufacturers that use Minoxidil sourced from IOL Chemicals.